Immuneering (NASDAQ:IMRX - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.16), Zacks reports.
Immuneering Stock Performance
Shares of NASDAQ IMRX traded down $0.06 during trading on Monday, reaching $1.74. The stock had a trading volume of 179,785 shares, compared to its average volume of 2,386,776. The business's 50-day moving average price is $1.79 and its 200-day moving average price is $2.00. Immuneering has a fifty-two week low of $1.00 and a fifty-two week high of $3.83. The company has a market cap of $54.03 million, a P/E ratio of -0.88 and a beta of -0.32.
Analysts Set New Price Targets
IMRX has been the subject of several recent analyst reports. Morgan Stanley cut Immuneering from an "equal weight" rating to an "underweight" rating in a research note on Friday, December 13th. Needham & Company LLC reissued a "buy" rating and set a $12.00 price objective on shares of Immuneering in a research report on Friday. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $13.00 target price on shares of Immuneering in a research report on Monday.
Get Our Latest Research Report on IMRX
Immuneering Company Profile
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Featured Articles
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
